Background: Exhaled nitric oxide (eNO) is a biomarker of airway inflammation and seems to precede respiratory symptoms, such as asthma, in childhood. Identifying genetic determinants of postnatal eNO levels might aid in unraveling the role of eNO in epithelial function or airway inflammation and disease. Objective: We sought to identify genetic determinants of early postnatal eNO levels and subsequent respiratory symptoms during the first year of life. Methods: Within a population-based birth cohort, eNO levels were measured in healthy term infants aged 5 weeks during quiet tidal breathing in unsedated sleep. We assessed associations of single nucleotide polymorphisms with eNO levels in a genome-wide association study and subsequent symptoms of lower respiratory tract infections during the first year of life and asked whether this was modified by prenatal and early-life environmental factors.
Exhaled nitric oxide (eNO) is an important biomarker of airway inflammation. Low levels of outdoor air pollution and environmental tobacco smoke affect eNO levels in newborns. 1, 2 Moreover, eNO levels seem to be an early marker for future respiratory morbidity in infants 3 and to precede transient early but not persistent wheeze in infants. 4 Thus it might help to differentiate early forms of infant wheeze, at least in subjects at risk. Later, eNO levels serve as an established indicator for allergic airway inflammation, aiding in discriminating childhood wheeze and asthma phenotypes [5] [6] [7] and identifying exacerbation risk or asthma control. 8, 9 Interestingly, respiratory epithelium-derived nitric oxide (NO) is also important for cell signaling. There is an emerging role of NO in airway development and pulmonary angiogenesis both in rodent models 10, 11 and premature children at risk for bronchopulmonary dysplasia. 12, 13 In the context of lung epithelial-mesenchymal crosstalk, 14 NO has been shown to modulate recovery from lung injury and to attenuate transition of epithelial cells to myofibroblasts. 15 In rodents this has important implications for epithelial function, structural maintenance, and lung remodeling in the postnatal phase. 16 However, in human subjects the role of the postnatal eNO level as a marker of epithelial function or for future respiratory morbidity, irrespective of underlying risk, remains unclear. Thus before it can be used as a marker for ''FeNOtyping, '' 6 it is important to better understand putative genetic determinants of postnatal eNO levels. Several lung cell types are able to produce NO from Larginine through the action of nitric oxide synthase (NOS) isoforms. 17, 18 Previous work in infants at risk of atopy 19 and after a candidate gene approach in older children [20] [21] [22] [23] has suggested that variants in genes, such as DENN/MADD domain containing 1B (DENND1B) and human nitric oxide synthase gene locus 2 (NOS2), can affect eNO levels. Only recently, a large genome-wide association study (GWAS) in subjects not at increased risk for atopy or asthma identified the loci human LYR motif containing 9 gene locus (LYRM9), NOS2, and one near the human gasdermin B gene locus (GSDMB) at 17q21 to be associated with eNO levels. 24 These latter analyses have been performed in older children in whom genetically determined eNO levels can also be affected by a number of other factors, such as concomitant disease and environmental effects. Here we present a GWAS in a unique and unselected population-based cohort of term-born infants not at increased risk of atopy or asthma: the Basel/Bern Infant Lung Development cohort. 25 In the cohort eNO levels measured shortly after birth and before the effect of environmental factors that can play a role in the pathophysiology of atopy or childhood asthma were shown to be unrelated to asthma diagnosis at school age. 26 We hypothesized that infant eNO levels could be determined by early genetic effects that can precede possible disease development from early in life.
METHODS
A more detailed description of the study population and methods is provided in the Methods section in this article's Online Repository at www. jacionline.org.
Study population and study participants
All data were collected in the ongoing prospective Basel/Bern Infant Lung Development birth cohort of unselected healthy neonates. 25 The study was approved by all involved ethics committees. All caregivers provided written informed consent for this study.
Measurements and quality control of tidal breathing and NO levels
Tidal breathing and mixed eNO levels were measured at 5 weeks of age, as described previously. 25, 27 Outcome parameters were tidal volume (V T ), minute ventilation (V9E 5 V T 3 respiratory rate), eNO level, and nitric oxide output (V9NO 5 eNO concentration 3 Expiratory flow). 27 Measurement of respiratory symptoms and time to recovery from first respiratory tract infection during the first year of life Respiratory symptom data were collected by weekly telephone interviews. 25 Respiratory symptoms were defined as ''cough, wheezing, difficulty breathing, and reduced activity during night and day.'' Weeks with symptoms were defined as the total number of weeks with respiratory symptoms. Time to recovery was defined as the total number of weeks that the infant had first respiratory symptoms during the first 6 and 12 months of life.
Genotyping and genetic data quality control
Whole-genome genotyping (Illumina HumanOmniExpress Bead Chips; Illumina, San Diego, Calif) was performed in 2 separate batches in all 425 study participants (in 2011 for 329 and in 2013 for an additional 96 children). We checked for a batch effect because of 2 genotyping time points. See Fig 1 for details on post hoc exclusion of subjects and quality control (QC) of eNO measurements and genotyping data. Principal component analysis was performed to obtain eigenvectors as covariates for later association tests. The first principal component was subsequently included for adjustment.
Statistical analyses and association testing
Analyses were restricted to additive models. No transformation was necessary for eNO or V9NO values. Associations between single nucleotide polymorphisms (SNPs) and eNO or V9NO values were analyzed by means of adjusted linear regression. The Bonferroni method was chosen to control for multiple testing.
Associations between SNPs and number of weeks with respiratory symptoms and time to recovery were analyzed by means of adjusted Poisson and logistic regression. For the latter, a binary variable (resolution of symptoms at <2 or > _2 weeks) was defined. Results are expressed as the incidence risk ratio (IRR) and odds ratio (OR), respectively. Gene-gene interaction and gene-environment interaction were assessed by means of ANOVA. The corresponding P value was labeled P int . A P value of less than .05 was considered significant.
Association computations were done in R, version 3.0.2, software (www. r-project.org) 28 by using the GenABEL package 29 and Stata 12.1 software (StataCorp, College Station, Tex) in both the final subset of all 229 subjects who were left for subsequent analyses and for each genotyping batch from either 2011 or 2013 separately. Replicating results for SNPs with significant associations with eNO levels in children, 21, 24 meta-analyses were performed by using the Metan package in Stata 11.2 software (StataCorp, College Station, Tex). Regional plots were generated by using LocusZoom (http://csg.sph.umich.edu/locuszoom). Permutation analyses were performed by chromosome with PLINK version 1.07. 30 Linkage disequilibrium (LD) was evaluated by using PLINK version 1.07 30 based on 1000 Genomes Project (CEU population) data. 31 Regional LD plots were generated in R 3.0.0 software. Base pair positions correspond to genome assembly GRCh37.p13, and gene annotations are according to the National Center for Biotechnology Information RefSeqGene Project (accessed March 24, 2015) .
In silico functional analyses
Expression and methylation quantitative trait loci were analyzed. Phylogenetic analyses were performed by using the Evolutionary Conserved Genomic Region Browser (http://ecrbrowser.dcode.org/). CCCTC-binding factor (CTCF)-binding sites and chromatin topological domains were determined by using data from CTCFBSDB 2.0 (http://insulatordb.uthsc. edu/). 32 Cell culture and gene expression analyses 
RESULTS
Between 1999 and 2013, the study enrolled 425 eligible infants, 353 of whom presented for lung function measurements at the age of 5 weeks after gestation. After secondary exclusion, technically acceptable data were obtained from 344 infants. As indicated in Fig 1, 229 subjects with data for 567,864 SNPs were then subjected to analyses. Table I presents anthropometric and demographic characteristics and distribution of known and possible covariates among all study participants for whom we had complete data sets on eNO measurements and from genotyping after aforementioned QC. eNO and V9NO values were highly correlated (r 5 0.71, P <.0001). We did not find any differences in baseline characteristics between infants for whom data were included or generally or specifically excluded from subsequent analyses (data not shown).
Calculated genomic inflation factors for eNO and V9NO values were less than 1.006, showing no evidence for population stratification. Although we could not replicate associations of SNPs in the DENND1B locus with eNO levels in infants at risk of developing allergy, 19 this was the case for SNPs in the NOS2 locus, 21 as well as variants in LYRM9 and GSDMB loci, 24 for their association with eNO levels in older children with the same effect direction, as previously published, 21, 24 although this did not reach genome-wide significance (see Fig E1 and Table E1 in this article's Online Repository at www.jacionline.org for forest plots of respective meta-analyses). However, after adjustment for confounders, as well as covariates, and correction for multiple testing, we identified different polymorphisms significantly associated with eNO and V9NO values. Two SNPs on 6q12 (reference SNP cluster codes rs208515 and rs208520) were in high LD (r 2 > 0.8) and significantly associated with eNO and V9NO values, respectively. The T allele (risk allele) of rs208515 and the G allele (risk allele) of rs208520 were associated with increased eNO (explained variance: 10.3% and 10.2%, respectively) and increased V9NO (explained variance: 9.9% and 9.9%, respectively) values. Two variants on 11p14 (rs12223678 and rs1441519) were also in high LD (r 2 > 0.8) and were indicative for associations with eNO and V9NO values. Here the T alleles (risk alleles) of rs1441519 and rs12223678 were associated with lower eNO levels (explained variance: 7.9% and 7.3%, respectively), as well as lower V9NO values (explained variance: 9.0% and 8.7%, respectively). Detailed association data for the total final subset of 229 subjects are provided in Tables E2, A and B, and summary statistics of associated SNPs are listed in Table E3 . Tables E4, A and B, for associations with eNO values). Moreover, they remained associated significantly with measured outcomes when we performed additional permutation analyses. For the 6q12 top SNPs, this was also the case after accounting for multiple testing within the permutation analysis, whereas for 11p14 hits, a trend was observed (see Table E5 for eNO levels).
In a previous study no association was found between postnatal eNO levels and respiratory symptoms during the first year of life for the entire study population, but such an association was found for the subgroup of mothers who smoked during pregnancy or were atopic. 3 Therefore we investigated whether the identified genetic determinants were also relevant for 209 of 229 children with respiratory symptoms during the first year of life. Table E6 , A, displays details on duration of respiratory symptoms in weeks for the study population and across group levels. The T allele of rs208515 (6q12) was negatively associated with the number of weeks with respiratory symptoms with an IRR of 0.80 (95% CI, 0.68-0.95; P 5 .009; Fig 3, A) . This was independent of symptom severity (data not shown) and remained significant also after adjusting for covariates (sex, having older siblings, nursery care, maternal atopy, maternal smoking during pregnancy, and V9E and eNO values) with an adjusted IRR of 0.81 (95% CI, 0.69-0.95; P 5.011; see Table E6 , B). The same association with comparable effect size and direction was found for rs208520. In contrast, we did not find any significant associations between 11p14 variants and the number of weeks with respiratory symptoms (see Table  E6 , B, for adjusted and Fig 3, B, for unadjusted results). Stratifying for maternal atopy or maternal smoking during pregnancy neither modified the association between SNPs and eNO or V9NO values nor between SNPs and subsequent symptoms for either locus. Furthermore, association of SNPs with assessed outcomes was not dependent of each other; that is, there was no genegene interaction for variants at 6q12 or 11p14 identified to be associated with eNO and V9NO values in infants (data not shown). Lastly, we analyzed whether the effect of identified genetic determinants was also relevant for the time to recovery from first respiratory tract infection. There was no effect of genetic determinants on the duration of first respiratory tract infection in the study population with symptoms across the first 12 months of life (n 5 207) in either univariable or adjusted models (data not shown). Constricting our analyses to children with symptoms during the first 6 months of life (n 5 130), however, rs208515 or rs208520 was significantly associated with faster recovery (ie, <2 weeks) in both univariable models (data not shown) and models adjusted for known and possible confounders and covariates (sex, age, having older siblings, nursery care, maternal (Fig 3, A) and rs1441519 (Fig 3, B) on mean eNO levels on the left (y-axis, eNO in ppb) and weeks with respiratory symptoms during the first year of life on the right (y-axis in weeks with symptoms) and their respective 95% CIs across genotypes (from left to right: homozygous for the nonrisk allele, heterozygous, and homozygous for the risk allele).
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 4 atopy, maternal smoking during pregnancy, season, being breastfed at time of first respiratory symptoms, and V9E and eNO values) with adjusted ORs of 0.34 (P 5.008) and 0.24 (P 5.002), respectively.
Because association signals on chromosome 6q12 (rs208515 and rs208520) and chromosome 11p14 (rs12223678 and rs1441519) are located in noncoding regions, we applied in silico and database analyses to search for putative causal SNPs in the respective regions driving the observed signals. The closest RefSeq genes identified on 6q12 were SLC25A51P1, EYS, and LOC441155, which are located upstream of rs208515 (at a distance of 446, 529, and 930 kb, respectively), whereas no gene was listed within 1000 kb downstream of rs208515 (Fig 4, A) . On 11p14, LUZP2 was the closest gene upstream of rs12223678 (distance of 812 kb). The closest downstream genes of rs1441519 were ANO3, MUC15, and SLC5A12 (at a distance of 424, 651, and 759 kb, respectively; Fig 4, B) . LD analyses in at least 1000 kb surrounding the associated polymorphisms on 6q12 identified an LD r 2 value of 0.8 or greater for 177 SNPs for rs208515 and 88 SNPs for rs208520. Because of r 2 values of 0.82 between rs208515 and rs208520, an overlap in tagged SNPs exists, resulting in 201 unique SNPs in the 6q12 tagging block (see Table E7 , A and B). None of the tagged SNPs is located in close vicinity to known genes in the 6q12 locus (closest SNP: rs1563929, which is located 203 kb from SLC25A51P1). Analysis for 11p14 identified an LD with an r 2 value of 0.96 between rs12223678 and rs1441519. Both SNPs are tagging for the identical set of SNPs at an r 2 value of 0.8 or greater (n 5 13 SNPs; see Table E7 , C and D). None of these 13 SNPs is in close vicinity to genes on the 11p14 locus (closest SNPs: rs11028996 at a distance of 802 kb to upstream LUZP2 and rs1348169 at a distance of 424 kb to downstream ANO3).
All identified SNPs (n 5 214) were subjected to further evaluation, irrespective of whether they locate within regulatory sequences, such as enhancers/superenhancers and insulators, transcription factor-binding sites, or evolutionary conserved regions determined in the respective regions, as depicted in Fig  4. Indeed, we identified 5 associated SNPs on chromosome 6q12 in binding sites for the CTCF, which is specifically allocated to insulator regions in human subjects and was shown to play an important developmental role (see Table E8 , A and B). [33] [34] [35] Three variants (rs9453663, rs9453664, and rs12200490) belong to a sequence that allows cell type-specific binding of CTCF in lung fibroblasts. The rs3899423 and rs4618506 polymorphisms locate in regions where CTCF binds in embryonic stem cells and lymphoblastoid cells, respectively. In silico predictions suggested that all 13 SNPs at 11p14 are located in an area that is part of 2 cell type-specific (human embryonic stem cells and fetal lung myofibroblasts, IMR-90) chromatin structures called topologically associating domains.
When we investigated whether genes located in the vicinity of the association signals from 6q12 (EYS) and 11p14 (SLC5A12, FIG 4 . Fine mapping of eNO association signals on chromosomes 6 and 11. LD analysis identified that no polymorphisms in linkage with the identified target SNPs at 6q12 (A, rs208515 and rs208520) and 11p14 (B, rs12223678 and rs1441519) are located in close vicinity to known genes (LD threshold: r 2 > _ 0.8). Database search identified that 5 tagged polymorphisms on chromosome 6 are located in CTCF-binding sites (rs4618506, rs3899423, rs9453663, rs9453664, and rs12200490; please note that only CTCF-binding sites matching to analyzed SNPs are depicted). In silico prediction proposed that the 11p14 locus contains cell type-specific chromatin structures called topologically associating domains, which encompass the LUZP2 and ANO3/MUC15 loci (domains are not specifically depicted because of their vast predicted extend of more than 3000 kb in embryonic stem cells and human lung fetal myofibroblasts). Plots were prepared with R software, version 3.0.0.
MUC15, and LUZP2) were expressed in specific cell types potentially relevant for NO production (see Table E9 in this article's Online Repository at www.jacionline.org), we found that genes from 11p14, but not 6q12, were expressed in lung epithelial cells. Therefore we hypothesized that 6q12 can have a broader regulatory effect, most likely on NOS genes in trans, whereas 11p14 genes can influence NO production more directly in lung epithelial cells. Consequently, we performed gene knockdown experiments on the 3 genes near the 11p14 locus in a lung epithelial cell line (H358) and measured NOS3 expression in these cells after knockdown (Fig 5) . Indeed, after an initial increase in NOS3 expression, possibly because of cell transfection stress, gene expression of NOS3 decreased after knockdown for all 3 genes, most prominently after SLC5A12 and MUC15 knockdown. This suggests that mutations in regulatory elements in the 11p14 region might have an effect on these 2 genes, in turn affecting NO production through NOS3, which is the only NO synthase present in lung epithelial cells, as indicated in Table E9 .
DISCUSSION
In this unselected birth cohort 25 we found 2 new loci, 6q12 and 11p14, to be associated with NO levels measured in healthy termborn infants shortly after birth. The 6q12 locus explains a significant proportion of variance at a reasonably high significance level. Furthermore, this locus is also inversely related to the number of weeks with respiratory symptoms and time to recovery after first verified respiratory symptoms during the first year of life and thus might be of functional relevance.
Our long-distance LD analyses revealed that no polymorphisms in LD with eNO-associated SNPs were located in close vicinity to thus far identified genes in the respective regions.
Therefore a direct effect of eNO-associated polymorphisms on gene function (eg, amino acid sequence changes, splicing, and promoter activity assays) in either of the 2 chromosomal loci could not be established.
The most significantly associated SNPs (rs208515 and rs208520) from 6q12 reside in a region that most likely has ''trans effects'' on mechanisms not necessarily located in the vicinity of the original association locus. Indeed, no expression of genes closest to the signal was observed in lung epithelial cells in our initial functional evaluation, and further investigations in this locus will be necessary. Unfortunately, existing expression quantitative trait locus data sets are of no use to study gene expression effects in early childhood, making further targeted experiments necessary. Interestingly, the extensive intergenic regions where identified SNPs are located are predicted to harbor regulatory regions. Five of the variants from associated tagging bins at 6q12 are placed in insulator sequences, which are defined as binding sites for the major human insulator protein CTCF. ChipSeq database-derived data revealed that CTCF binds in a cell typespecific manner and, more importantly, in cell types involved in embryotic development and potentially relevant to the course of airway inflammation (lung fibroblasts and lymphoblastoid cells). [33] [34] [35] The second identified locus at 11p14 (rs12223678 and rs1441519) is situated in the vicinity of the human ANO3/ MUC15 gene locus. Although ANO3 belongs to a gene family encoding calcium-activated chloride channels, 36 the MUC15 protein belongs to the mucin family, representing glycoproteins, which constitute a part of the physical barrier of the airway epithelium. 36 Remarkably, it also shares structural motifs with the human epithelial growth factor (EGF) receptor and has been shown to modulate EGF receptor signaling after EGF stimulation. 37 EGF and homologs regulate several signal cascades 38, 39 that participate in functions, such as proliferation, differentiation, mitosis, cell survival, and apoptosis, on the transcription level. 38 Additional downstream events encompass glucose metabolism and cell migration.
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SLC5A12 was identified as a further candidate gene potentially contributing to the observed association with eNO levels through NOS3 expression. This gene is a member of the solute-linked carrier gene family 5 (SLC5) that contains the low-affinity Na(1)-coupled lactate transporter. 40 It has been shown that the activity of SGLT1 (also known as SLC5A1) protein, a member of the SLC5 gene family as well, is regulated by NOS3. 41 However, how exactly these genes on 11p14 are involved in eNO-related mechanisms remains unknown and would need to be investigated further. Prediction analysis for the 11p14 variants indicates cell type-specific CTCF-driven formation of topologically associated domains in embryonic stem cells and fetal lung fibroblasts, potentially orchestrating 11p14 chromatin rearrangements and affecting genes involved in lung tissue development.
Chromatin insulators regulate the effects of enhancers and silencers on a gene promoter 42, 43 and thus might induce or suppress transcription activity. Moreover, insulator activity is mainly driven by DNA conformation and the global chromatin architecture mediated by CTCF, 33 which has been identified as a major regulator in the genome. 33, 34 CTCF establishes boundaries between topologically associating domains in a cell type-specific and developmental fashion. 34, 44 Importantly, we measured levels of mixed eNO in our study (ie, eNO comprised of nasal and bronchial origin). There are no data supporting a difference between strictly oral or nasal NO in term infants. 27, 45 However, such differences could be demonstrated for premature infants very early in life and before any possible significant bacterial colonization and pneumatization of paranasal sinuses, with much higher levels for nasal NO, predominantly under inducible NOS influence, 17 than for bronchial eNO. 46, 47 The link to the already mentioned role of NO metabolism in cell signaling, vascular endothelial growth factor2mediated airway development, 10-13 lung epithelial-mesenchymal crosstalk, 14 and epithelial function is striking. These are functional implications and must be considered with caution. Moreover, further genes adjacent to the most significant SNPs at 6q12 and 11p14 might also play their roles.
Remarkably, we found an association with known genetic determinants of eNO levels in neither children at risk of atopy (data not shown) 19 nor older children (see the Results section and this article's Online Repository at www.jacionline.org) 22, 24 or adults (data not shown) 20 ,23,48 on a genome-wide level. However, such replications of previously published associations in our cohort on a genome-wide level were also unexpected because eNO levels at a later age more typically reflect the effect of factors that can play a role in the pathophysiology of atopy or childhood asthma. We were also unable to replicate our findings in another population (ie, in study participants of a follow-up of the GABRIEL study) in whom eNO levels were measured, although at an older mean age of 9.9 years (data not shown). 49 Interestingly, the ANO3/MUC15 locus at 11p14 has recently been related to atopic eczema in adults ascertained through asthma, 36 but the genetic signal in that study was independent from the signal found in our study. Earlier in this study, the role of infant eNO as a marker for later respiratory symptoms was evident for the subgroup of smoking or atopic mothers. 3 This has been corroborated by others. 4 We investigated the potential discrepancy to current findings and found several differences. The population included by Latzin et al 3 was smaller and had higher exposure to environmental tobacco smoke (14.0% in Latzin et al vs 8.7%) or air pollution. Furthermore, siblings were strictly excluded in the current study. We reproduced the former findings for the smaller population used by Latzin et al. 3 We speculate that discrepancies could be due to sample size differences or differences in environmental exposure.
To the best of our knowledge, this study is the first effort thus far to uncover genetic determinants of eNO levels, which were collected in healthy term infants shortly after birth, 25 according to the latest standards and already published as part of a set of normative data, including extensive QC during data collection, and subsequent analyses. 27 Despite being the first effort thus far, we are limited by the number of healthy subjects very early in life included to generate sufficient statistical power to detect all variants with at least modest effects and especially with regard to possible replication in independent populations. To our knowledge, no such cohort exists, and a decade was required to build up the present study. Still, analyses within the 2 different batches might nevertheless serve as discovery and replication samples for our identified determinants of eNO levels in healthy infants shortly after birth. Analyzing both batches separately, they display the same effects, with the same effect direction and comparable effect sizes while showing different levels of significance given their unequal numbers of subjects. Moreover, with this GWAS, we were able to reach genome-wide significance levels with a significant effect size, even with the most conservative method to adjust for multiple testing and with significant results for the identified top SNPs also after permutation. Still, larger longitudinal studies are needed to characterize functional implications, as well as further loci with only modest effects that remain to be identified for eNO levels in later life.
In conclusion, limited by small sample size and the lack of a formal replication in an independent population in general, we nevertheless identified novel genetic determinants of the most accurately measured postnatal eNO levels in healthy infants not at increased risk for atopy or asthma. One identified locus was 6q12, which most likely has ''trans effects'' on mechanisms not necessarily located in the vicinity of the originally associated locus but for which rs208515 explained up to 10.3% of outcome variance with a high level of significance. In addition, suggestive association in the GWAS was detected for SNPs at chromosome 11p14, for which functional analyses revealed effects on NOS3 expression. Given the association with respiratory symptoms, these results might provide new insight into possible biological mechanisms underlying eNO levels, their regulation, and their functional relevance within the spectrum of respiratory diseases in young children. The identification of these variants might implicate that postnatal eNO metabolism in healthy infants not at increased risk for atopy is rather related to epithelial function before first viral infections and postnatal sensitization than to mechanisms associated with asthma, atopy, or increased risk thereof later in life.
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Key messages
d Genetic determinants at 6q12 and 11p14 are associated with higher postnatal eNO levels in healthy term-born infants, whereas there were no associations on a genomewide level with known genetic determinants of eNO in later life.
d Although genetic determinants at 6q12 can act in ''trans'' and appear to be associated subsequently with less and less extensive respiratory symptoms during the first year of life in our study population, those at 11p14 seem to affect NOS3 expression in lung epithelial cells.
d Our findings imply potential differences in the relation between eNO metabolism and lung disease in early infancy in comparison with later childhood.
